The purpose of this study is to assess safety, tolerability and pharmacokinetics of AZD2423 in young and elderly healthy Japanese volunteers.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Enrollment
19
Research Site
Fukuoka, Japan
Number of participants with Adverse events
Time frame: Ranging from screening visit (Visit Day 1) to follow-up visit (Visit Day 3)
Vital signs
Changes from baseline in systolic blood pressure, pulse rate and body temperature
Time frame: Ranging from screening visit (Visit Day 1) to follow-up visit (Visit Day 3)
Electrocardiograms
Time frame: Ranging from screening visit (Visit Day 1) to follow-up visit (Visit Day 3)
Laboratory Variables (hematology, urinalysis and clinical chemistry)
Time frame: Ranging from screening visit (Visit Day 1) to follow-up visit (Visit Day 3)
Plasma concentration over time
Time frame: Pre-dose, 20 and 40 minutes, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 60 and 72 hours after the first dose
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.